Evidence map›Paper›PMID 30590790›Full record

ArticleRheumatology (Oxford, England)2019

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.

Jeffrey R Curtis, Darl D Flake, Michael E Weinblatt, Nancy A Shadick, Mikkel Østergaard, Merete Lund Hetland, Cecilie Heegaard Brahe, Yong Gil Hwang, Daniel E Furst, Vibeke Strand and 8 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jeffrey R CurtisDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL.
Darl D FlakeMyriad Genetics Inc., Salt Lake City, UT.
Michael E WeinblattDepartment of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA.
Nancy A ShadickDepartment of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA.
Mikkel ØstergaardCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre For Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Internal Medicine, University of Copenhagen, Copenhagen, Denmark.
Merete Lund HetlandCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre For Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Internal Medicine, University of Copenhagen, Copenhagen, Denmark.
Cecilie Heegaard BraheCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre For Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Internal Medicine, University of Copenhagen, Copenhagen, Denmark.
Yong Gil HwangDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Daniel E FurstDavid Geffen School of Medicine at UCLA, UCLA, Los Angeles.
Vibeke StrandDivision of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA.
Carol J EtzelAnderson Cancer Center, University of Texas School of Public Health, Houston, TX, USA.
Dimitrios A PappasDivision of Rheumatology, Columbia University, New York, NY, USA.
Xingbin WangCrescendo Bioscience Inc., South San Francisco, CA, USA.
Ching Chang HwangCrescendo Bioscience Inc., South San Francisco, CA, USA.
Eric H SassoCrescendo Bioscience Inc., South San Francisco, CA, USA.
Alexander GutinMyriad Genetics Inc., Salt Lake City, UT.
Elena HitrayaCrescendo Bioscience Inc., South San Francisco, CA, USA.
Jerry S LanchburyMyriad Genetics Inc., Salt Lake City, UT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop and evaluate an adjusted score for the multi-biomarker disease activity (MBDA) test to account for the effects of age, sex and adiposity in patients with RA.

methodsTwo models were developed to adjust MBDA score for age, sex and adiposity, using either serum leptin concentration or BMI as proxies for adiposity. Two cohorts were studied. A cohort of 325 781 RA patients who had undergone commercial MBDA testing and had data for age, sex and serum leptin concentration was used for both models. A cohort of 1411 patients from five studies/registries with BMI data was used only for the BMI-adjusted MBDA score. Univariate and multivariate linear regression analyses evaluated the adjusted MBDA scores and conventional clinical measures as predictors of radiographic progression, assessed in terms of modified total Sharp score (ΔmTSS).

resultsTwo models were developed, based on findings that MBDA score was higher in females than males and increased with age, leptin concentration and BMI. In pairwise regression analyses, the leptin-adjusted (P = 0.00066) and BMI-adjusted (P = 0.0027) MBDA scores were significant independent predictors of ΔmTSS after adjusting for DAS28-CRP, whereas DAS28-CRP was not, after adjusting for leptin-adjusted (P = 0.74) or BMI-adjusted (P = 0.87) MBDA score. Moreover, the leptin-adjusted MBDA score was a significant predictor of ΔmTSS after adjusting for the BMI-adjusted MBDA score (P = 0.025) or the original MBDA score (0.027), whereas the opposite was not true.

conclusionLeptin-adjusted MBDA score significantly adds information to DAS28-CRP and the original MBDA score in predicting radiographic progression. It may offer improved clinical utility for personalized management of RA.

Indexed as

AdiposityAge FactorsSeverity of Illness IndexSex FactorsAdultAgedArthritis, RheumatoidBiomarkersBody Mass IndexCohort StudiesDisease ProgressionFemaleHumansLeptinMaleMiddle AgedBiomarkersLeptinbiomarkerdisease activityleptinMBDAmulti-biomarker disease activityradiographic progressionrheumatoid arthritisVectra DA

Identifiers

PMID30590790
PMCPMC6477524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.